Advisory Committee Recommends Sanofi’s Pentacel Combo Vaccine
This article was originally published in The Pink Sheet Daily
Concerns regarding insufficient Haemophilus influenzae type b efficacy data are not great enough for committee members to withhold recommendation.
You may also be interested in...
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?